Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Despite the long history of Traditional Chinese Medicine (TCM) in disease treatment, the underlying "Jun-Chen-Zuo-Shi" principle remains largely unexplored. To address this gap, it is essential to elucidate the interactions between active substances in TCM through quantitative molecular and cellular pharmacology. The Chou-Talalay method is particularly effective for investigating drug combinations, making it highly relevant for TCM formulas. This study employed the Chou-Talalay method to explore the drug-drug interactions in Xuebijing (XBJ), a TCM formula used for treating sepsis. The aim was to elucidate the "Jun-Chen-Zuo-Shi" principle by investigating the interactions of the main active substances in XBJ: danshensu and salvianolic acid B (from Radix Salviae Miltiorrhizae), senkyunolide A (from Rhizoma Chuanxiong), ligustilide (from Radix Angelicae Sinensis), safflower yellow and hydroxysafflor yellow A (from Flos Carthami), and paeoniflorin (from Radix Paeoniae Rubra). We quantitatively analyzed their TLR4 antagonistic activities and used the combination index (CI) to quantify their interactions, revealing synergism (CI < 1), additive effects (CI = 1), and antagonism (CI > 1). The results show these agents inhibit nitric oxide (NO) production, with some combinations demonstrating synergistic effects at certain concentrations, while others present antagonistic effects. Understanding these interactions provides a scientific foundation for optimizing TCM formulations, enhancing quality control, efficacy, and safety.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961611PMC
http://dx.doi.org/10.1038/s41598-025-95994-9DOI Listing

Publication Analysis

Top Keywords

drug-drug interactions
8
interactions active
8
"jun-chen-zuo-shi" principle
8
active substances
8
chou-talalay method
8
interactions
6
tcm
5
quantitative analysis
4
analysis drug-drug
4
active components
4

Similar Publications

Preface to DMR drug-drug interactions special issue.

Drug Metab Rev

August 2025

Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc, Boston, MA, USA.

View Article and Find Full Text PDF

Background: The COVID-19 antiviral Nirmatrelvir/Ritonavir (Paxlovid, N/R) was approved for use in Canada in January 2022, with the Government of Canada assuming a procurement role and provinces, territories, and federal departments implementing usage within their respective healthcare systems. The objective of this analysis is to describe how N/R was implemented across various jurisdictions in the first six months after it was available for use and identify promising implementation practices.

Methods: Fourteen semi-structured discussions in small group settings were conducted with jurisdictional representatives involved in the implementation of N/R.

View Article and Find Full Text PDF

Motivation: The increasing demand for effective drug combinations has made drug-drug interaction prediction a critical task in modern pharmacology. While most existing research focuses on small-molecule drugs, the role of biotech drugs in complex disease treatments remains relatively unexplored. Biotech drugs, derived from biological sources, have unique molecular structures that differ significantly from those of small molecules, making their interactions more challenging to predict.

View Article and Find Full Text PDF

Background: Membrane transport proteins are critical determinants of systemic and intracellular drug levels, thereby contributing substantially to drug response and/or adverse drug reactions. Therefore, the U.S.

View Article and Find Full Text PDF

Background: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.

View Article and Find Full Text PDF